摘要
目的探讨CD_(133)、CD_(44)、CD_(11b)在急性髓系白血病(AML)中的表达,并分析CD_(133)、CD_(44)、CD_(11b)与临床预后的相关性。方法选取2020年12月至2022年6月在我院诊治的AML患者50例作为试验组,并选取同期入院的良性血液病患者20例作为对照组,比较两组CD_(133)、CD_(44)、CD_(11b)阳性表达情况,并分析CD_(133)阳性与阴性、CD_(44)阳性与阴性、CD_(11b)阳性与阴性的临床治疗疗效,以及复发情况和预后生存情况。结果试验组CD_(133)阳性率、CD_(44)阳性率、CD_(11b)阳性率分别为42.00%、52.00%、46.00%,明显高于对照组的10.00%、5.00%、15.00%(P<0.05)。CD_(133)阴性的临床治疗疗效优于CD_(133)阳性,且CD_(133)阴性的CR率为57.14%,明显高于CD_(133)阳性的23.53%(P<0.05);CD_(44)阴性的临床治疗疗效优于CD_(44)阳性,且CD_(44)阴性的CR率为70.83%,明显高于CD_(44)阳性的14.29%(P<0.05);CD_(11b)阴性的临床治疗疗效优于CD_(11b)阳性,且CD_(11b)阴性的CR率为59.26%,明显高于CD_(11b)阳性的22.22%(P<0.05)。CD_(133)阳性、CD_(44)阳性、CD_(11b)阳性患者复发率分别为63.16%、66.67%、61.11%,明显高于CD_(133)阴性、CD_(44)阴性、CD_(11b)阴性患者(36.84%、33.33%、38.89%)(P<0.05)。Log Rank(Mantel-Cox)检验显示,CD_(133)阴性、CD_(44)阴性、CD_(11b)阴性患者1年OS率分别为79.31%、83.33%、81.48%,明显高于CD_(133)阳性、CD_(44)阳性、CD_(11b)阳性患者的47.62%、50.00%、47.83%(P<0.05)。结论AML患者CD_(133)、CD_(44)、CD_(11b)阳性表达较高,且CD_(133)、CD_(44)、CD_(11b)阳性患者治疗疗效较差,复发率较高,预后生存较差。
Objective To investigate the expression of CD_(133),CD_(44),CD_(11b) in acute myeloid leukemia(AML),and analyze the correlation between CD_(133),CD_(44),CD_(11b) and clinical prognosis.Methods Fifty patients with AML who were diagnosed and treated in our hospital from December 2020 to June 2022 were selected as the experimental group,and 20 patients with benign hematological diseases who were admitted in the same period were selected as the control group.The positive expression of CD_(133),CD_(44),and CD_(11b) in the two groups were compared,and the clinical therapeutic effects of CD_(133) positive and negative,CD_(44) positive and negative,CD_(11b) positive and negative,as well as the recurrence and prognosis survival were analyzed.Results The positive rates of CD_(133),CD_(44) and CD_(11b) in the experimental group were 42.00%,52.00%and 46.00%respectively,which were significantly higher than those in the control group(10.00%,5.00%and 15.00%,P<0.05).The clinical curative effect of CD_(133) negative was better than that of CD_(133) positive,and the CR rate of CD_(133) negative was 57.14%,significantly higher than that of CD_(133) positive 23.53%(P<0.05);The clinical treatment effect of CD_(44) negative is better than that of CD_(44) positive,and the CR rate of CD_(44) negative is 70.83%,which is significantly higher than that of CD_(44) positive 14.29%(P<0.05);The clinical treatment effect of CD_(11b) negative is better than that of CD_(11b) positive,and the CR rate of CD_(11b) negative is 59.26%,which is significantly higher than that of CD_(11b) positive 22.22%(P<0.05).The recurrence rates of CD_(133) positive,CD_(44) positive and CD_(11b) positive patients were 63.16%,66.67%and 61.11%respectively,which were significantly higher than those of CD_(133) negative,CD_(44) negative,CD_(11b) negative patients(36.84%,33.33%and 38.89%,P<0.05).Log Rank(Mantel-Cox)test showed that the one-year OS rate of CD_(133) negative,CD_(44) negative and CD_(11b) negative patients was 79.31%,83.33%and 81.48%respectively,which was significantly higher than 47.62%,50.00%and 47.83%of CD_(133) positive,CD_(44) positive and CD_(11b) positive patients(P<0.05).Conclusion The positive expression of CD_(133),CD_(44) and CD_(11b) in AML patients is high,and the treatment effect of CD_(133),CD_(44) and CD_(11b) positive patients is poor,the recurrence rate is high,and the prognosis is poor.
作者
魏孝艾
朱翠
孙积峰
刘慧娥
付丽丽
WEI Xiaoai;ZHU Cui;SUN Jifeng;LIU Hui'e;FU Lili(Department of Oncology and Hematology,Jinan Eighth People's Hospital,Jinan 271104,China;Department of Laboratory,Jinan Eighth People's Hospital,Jinan 271104,China)
出处
《中国医药指南》
2023年第9期7-10,共4页
Guide of China Medicine
基金
济南市卫生健康委员会第二批科技计划项目(编号:2020-4-148)。
